ES2659718T3 - Anticuerpos anti-GT468 monoclonales para el tratamiento del cáncer - Google Patents

Anticuerpos anti-GT468 monoclonales para el tratamiento del cáncer Download PDF

Info

Publication number
ES2659718T3
ES2659718T3 ES09778564.6T ES09778564T ES2659718T3 ES 2659718 T3 ES2659718 T3 ES 2659718T3 ES 09778564 T ES09778564 T ES 09778564T ES 2659718 T3 ES2659718 T3 ES 2659718T3
Authority
ES
Spain
Prior art keywords
seq
dsm
antibody
dna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09778564.6T
Other languages
English (en)
Spanish (es)
Inventor
Ugur Sahin
Özlem TÜRECI
Michael Koslowski
Rita Mitnacht-Kraus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johannes Gutenberg Universitaet Mainz
Ganymed Pharmaceuticals GmbH
Original Assignee
Johannes Gutenberg Universitaet Mainz
Ganymed Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johannes Gutenberg Universitaet Mainz, Ganymed Pharmaceuticals GmbH filed Critical Johannes Gutenberg Universitaet Mainz
Application granted granted Critical
Publication of ES2659718T3 publication Critical patent/ES2659718T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09778564.6T 2008-09-16 2009-09-16 Anticuerpos anti-GT468 monoclonales para el tratamiento del cáncer Active ES2659718T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9745308P 2008-09-16 2008-09-16
EP08016277 2008-09-16
EP08016277A EP2166021A1 (en) 2008-09-16 2008-09-16 Monoclonal antibodies for treatment of cancer
US97453P 2008-09-16
PCT/EP2009/006704 WO2010031551A2 (en) 2008-09-16 2009-09-16 Monoclonal antibodies for treatment of cancer

Publications (1)

Publication Number Publication Date
ES2659718T3 true ES2659718T3 (es) 2018-03-19

Family

ID=40589589

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09778564.6T Active ES2659718T3 (es) 2008-09-16 2009-09-16 Anticuerpos anti-GT468 monoclonales para el tratamiento del cáncer

Country Status (27)

Country Link
US (1) US8946388B2 (https=)
EP (3) EP2166021A1 (https=)
JP (1) JP2012502938A (https=)
KR (1) KR101818741B1 (https=)
CN (3) CN102164963B (https=)
AU (1) AU2009294896B2 (https=)
BR (1) BRPI0918178B8 (https=)
CA (1) CA2732594C (https=)
CY (1) CY1119956T1 (https=)
DK (1) DK2342234T3 (https=)
ES (1) ES2659718T3 (https=)
HK (1) HK1253579A1 (https=)
HR (1) HRP20180262T1 (https=)
HU (1) HUE036477T2 (https=)
IL (2) IL211010A (https=)
LT (1) LT2342234T (https=)
MX (2) MX357010B (https=)
NO (1) NO2342234T3 (https=)
NZ (2) NZ591004A (https=)
PL (1) PL2342234T3 (https=)
PT (1) PT2342234T (https=)
RS (1) RS56937B1 (https=)
SI (1) SI2342234T1 (https=)
SM (1) SMT201800079T1 (https=)
TR (1) TR201802090T4 (https=)
WO (1) WO2010031551A2 (https=)
ZA (1) ZA201100835B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP4464384A3 (en) 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
RU2597831C2 (ru) * 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
US20130236890A1 (en) * 2012-03-08 2013-09-12 HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells
KR101471253B1 (ko) * 2012-10-29 2014-12-10 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
JP2017521998A (ja) * 2014-05-12 2017-08-10 ヌマブ アクチェンゲゼルシャフト 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3770171A1 (en) * 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
WO2017011559A1 (en) * 2015-07-14 2017-01-19 Medlmmune, Llc Compositions and methods for treating cancer
KR20180039726A (ko) 2015-09-04 2018-04-18 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 인슐린 면역글로불린 융합 단백질
MA43365A (fr) * 2015-12-01 2018-10-10 Genmab Bv Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
BR112019008010A2 (pt) 2016-10-20 2019-07-09 I-Mab anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN106632661A (zh) * 2017-01-10 2017-05-10 天津东亚生物技术有限公司 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用
JP2020513819A (ja) * 2017-03-15 2020-05-21 スージョウ ギャラクシー バイオファーマ カンパニー リミテッド Ｃｔｌａ４抗体、医薬組成物およびその使用
CN107556369A (zh) * 2017-08-23 2018-01-09 天津国际生物医药联合研究院 一种抗原肽和用于检测肿瘤细胞的抗体制备方法及其应用
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN109402064B (zh) * 2018-11-05 2021-05-14 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
KR102266418B1 (ko) * 2019-07-30 2021-06-16 한국생명공학연구원 영여자 추출물을 유효성분으로 함유하는 전립선 질환의 예방 및 치료용 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5744585A (en) * 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003075014A2 (en) 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
WO2004065629A1 (en) 2003-01-17 2004-08-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CN1663603A (zh) 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
LT2398902T (lt) * 2009-02-20 2023-12-27 Astellas Pharma Inc. Vėžio diagnostikos ir gydymo būdai bei kompozicijos
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer

Also Published As

Publication number Publication date
SMT201800079T1 (it) 2018-03-08
BRPI0918178A2 (pt) 2015-12-01
EP2166021A1 (en) 2010-03-24
MX357010B (es) 2018-06-22
IL242204B (en) 2020-09-30
BRPI0918178A8 (pt) 2020-05-19
MX2011002856A (es) 2011-06-28
BRPI0918178B1 (pt) 2021-04-06
HK1253579A1 (en) 2019-06-21
BRPI0918178B8 (pt) 2021-05-25
EP2342234B1 (en) 2017-11-15
JP2012502938A (ja) 2012-02-02
NO2342234T3 (https=) 2018-04-14
IL242204A0 (en) 2015-11-30
AU2009294896B2 (en) 2015-04-30
CA2732594C (en) 2019-05-28
CN102164963B (zh) 2015-07-29
PT2342234T (pt) 2018-02-21
CN104628858B (zh) 2018-11-16
CN104628858A (zh) 2015-05-20
CN102164963A (zh) 2011-08-24
DK2342234T3 (en) 2018-02-26
WO2010031551A2 (en) 2010-03-25
ZA201100835B (en) 2014-04-30
RS56937B1 (sr) 2018-05-31
HRP20180262T1 (hr) 2018-03-23
CY1119956T1 (el) 2018-12-12
IL211010A (en) 2015-11-30
IL211010A0 (en) 2011-04-28
SI2342234T1 (en) 2018-04-30
EP3312198A1 (en) 2018-04-25
NZ591004A (en) 2012-03-30
LT2342234T (lt) 2018-03-12
TR201802090T4 (tr) 2018-03-21
CN105753988A (zh) 2016-07-13
CA2732594A1 (en) 2010-03-25
NZ596490A (en) 2013-05-31
EP2342234A2 (en) 2011-07-13
KR20110055699A (ko) 2011-05-25
WO2010031551A3 (en) 2010-09-16
KR101818741B1 (ko) 2018-01-15
AU2009294896A1 (en) 2010-03-25
US8946388B2 (en) 2015-02-03
PL2342234T3 (pl) 2018-07-31
HUE036477T2 (hu) 2018-07-30
US20110223182A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
ES2659718T3 (es) Anticuerpos anti-GT468 monoclonales para el tratamiento del cáncer
ES2857500T3 (es) Anticuerpo anti-mesotelina y composición que comprende el mismo
ES2708124T3 (es) Procedimiento para preparar moléculas heteromultiméricas
ES2633810T3 (es) Proteínas de unión a antígeno humanas que se unen a beta-Klotho, receptores de FGF y complejos de los mismos
AU2011324870B2 (en) pan-HER antibody composition
DK2675826T3 (en) Antibody to CSF-1R
JP6258194B2 (ja) 抗神経成長因子抗体並びに前記の製造及び使用方法
JP5719596B2 (ja) 抗体及びその誘導体
CA2821130C (en) Anti-notch1 antibodies
WO2017148424A1 (zh) 一种pdl-1抗体、其药物组合物及其用途
JP2012507299A (ja) Ｌｉｇｈｔ標的分子およびその使用
WO2023241629A1 (zh) 抗cldn18.2抗体、其药物组合物及用途
WO2023109888A1 (zh) 抗ang2-vegf双特异性抗体及其用途
US8128932B2 (en) Anti-VEGFR monoclonal antibody, method of making and uses thereof
CN110799211B (zh) 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
ES2694679T3 (es) Epitopos de antígeno de superficie receptor de factor de crecimiento epidérmico y uso de los mismos
JP7466930B2 (ja) 抗ｃｄ１３７抗体およびその使用
KR20240099289A (ko) 항-cldn18.2 항체 및 그의 용도
CN111675763A (zh) 抗met和ron双特异性抗体及其抗体-药物偶联物的制备和应用
US20250195645A1 (en) Combination of multispecific molecule and immune checkpoint inhibitor
WO2025247171A1 (en) Anti-mesothelin antibodies
HK40105696A (zh) 新的间皮素抗体和包含其的组合物
WO2025237392A1 (zh) 新型抗egfr抗体、药物偶联物及其用途
WO2024093147A1 (zh) 一种特异性结合CD44的v5外显子的抗体及其用途
WO2026057702A1 (en) Claudin-1/egfr bispecific antibodies